GLP-1 Market
LLY $1417.99 ▲ +0.6% NVO $42.18 ▲ +5.0% PFE $30.79 ▲ +2.6% VKTX $27.97 ▲ +7.2% KLRA $12.80 ▲ +1.7% GPCR $20.36 ▲ +0.0% RHHBY $60.95 ▲ +3.0%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

HBI0101 CART

HBI0101 CART

Company
Polina Stepensky
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
3 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

3 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Nov 5, 2026

Find a Clinical Trial Near Me

See recruiting studies for HBI0101 CART and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06971380

    Study of HBI0101 (NXC-201) CAR-T Therapy in Multiple Myeloma and Light-Chain Amyloidosis

    Not yet reported Polina Stepensky 180 participants Est. completion 2030-05-15 1 site Stand-alone
    Other conditions: Multiple Myeloma, Refractory to Standard Treatment, Multiple Myeloma, Relapsed, Light Chain Amyloidosis
    View official trial listing →
  • Recruiting NCT NCT07085676

    Phase 1 Study of HBI0101 CAR-T in Refractory B-Cell Autoimmune Diseases

    Not yet reported Polina Stepensky 120 participants Est. completion 2030-11-01 1 site Stand-alone
    Other conditions: Systemic Sclerosis (SSc), Idiopathic Inflammatory Myopathy (IIM), Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis (MS) Secondary Progressive, Neuromyelitis Optica Spectrum Disorder (NMOSD), Myasthenia Gravis (MG), Antiphospholipid Antibody Syndrome
    View official trial listing →
  • Recruiting NCT NCT07333430

    Study of Naive HBI0101 CAR-T Therapy in Relapsed/Refractory Multiple Myeloma

    Not yet reported Hadassah Medical Organization 60 participants Est. completion 2030-12-01 1 site Stand-alone
    Other conditions: Relapsed/Refractory Multiple Myeloma (MM)
    View official trial listing →
  • Active, not recruiting NCT NCT04720313

    NXC-201 (formerly HBI0101) Multiple Myeloma

    Not yet reported Hadassah Medical Organization 160 participants Est. completion 2027-01 1 site
    Other conditions: Dose Escalation and Safety
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.